Related Experiment Videos
Conventional induction treatments do not influence overall survival in multiple myeloma
M Boccadoro1, A Palumbo, C Argentino
1Dipartimento di Medicina ed Oncologia Sperimentale, Azienda Ospedaliera San Giovanni, Torino, Italy.
Abstract:
A retrospective analysis was performed on two subsequent myeloma patient series treated with the same conventional induction treatments, melphalan and prednisone or alternating VMCP/VBAP: 273 were enrolled in the multicentre M83 trial (M83 trial group) from 1983 to 1986; 160 were referred to a single institution (Haemat. To group) from 1986 to 1994. Response to treatment was very similar in the two groups (53% v 50.3%). Remission duration curves merely overlapped (median 20 v 21 months). However, overall survival was significantly longer in the Haemat. To group (43.2 v 33 months, P < 0.04). This difference was due to a prolonged period from relapse or progression to death (21 v 8 months, P < 0.01; 20.8 v 7 months, P < 0.009). Prolonged survival was also observed in poor-prognosis patients with a serum beta2-microglobulin level > 3 mg/l, in the Haemat. To group (31.8 v 24.2 months, P < 0.04). The same induction treatments produced almost identical response rate and remission duration in both groups, but overall survival was 10 months longer for one group. However, it could be argued that treatment salvage modalities and support therapies have been improved in a decade. Lastly, induction treatments did not influence overall survival.
Insights
This study compared myeloma patient outcomes using conventional treatments. While initial responses and remission durations were similar, one group showed significantly longer overall survival, possibly due to improved salvage therapies over time.
Area of Science:
- Hematology
- Oncology
- Clinical Research
Background:
- Multiple myeloma treatment has evolved, necessitating comparisons of outcomes with conventional therapies.
- Understanding survival differences in myeloma patients is crucial for optimizing treatment strategies.
Purpose of the Study:
- To compare the efficacy of conventional induction treatments in two distinct multiple myeloma patient cohorts.
- To investigate factors influencing overall survival and remission duration in myeloma.
Main Methods:
- Retrospective analysis of two myeloma patient series (M83 trial group and Haemat. To group) treated with melphalan and prednisone or VMCP/VBAP.
- Comparison of response rates, remission duration, and overall survival between the two groups.
Main Results:
- Similar treatment response rates (53% vs. 50.3%) and remission durations (median 20 vs. 21 months) were observed.
- Overall survival was significantly longer in the Haemat. To group (43.2 vs. 33 months, P < 0.04).
- This survival difference was attributed to a prolonged period from relapse to death, particularly in poor-prognosis patients.
Conclusions:
- Conventional induction treatments yielded comparable initial responses and remission durations.
- Overall survival in multiple myeloma may be influenced by factors beyond initial induction therapy, such as improved salvage treatments.
- Further research is needed to elucidate the impact of evolving supportive care on long-term myeloma outcomes.